On May 15, 2020, Simcere announced that key clinical data from a strategic cooperation on KN035, also known as Envafolimab, will be released at the upcoming annual meeting of ASCO 2020 in the US. The project is a collaboration with Alphamab (Jiangsu) Co. Ltd and 3D Medicines (Beijing) Technology Co., Ltd. on the PD-L1 antibody KN035, a checkpoint inhibitor for programmed cell death ligand-1 (PD-L1), for tumor therapies in mainland China. The newly-released data are expected to focus on the monotherapy of tumors with high microsatellite instability (MSI-H) and advanced solid tumors with mismatch-repair deficiency (dMMR), and the combination chemotherapy of advanced gastric tumors and gastroesophageal junction (G/GEJ) tumors.
Mr. Ren Jinsheng, founder and chairman of Simcere, said: "There has been steady and rapid progress of Envafolimab since the launch of the strategic cooperation with Alphamab and 3D Medicines on Envafolimab on March 30, 2020. The clinical data released at the ASCO meeting is expected to show that Envafolimab has high levels of safety and long-lasting anti-tumor activity for multiple indications. All these data make us believe that this PD-L1 subcutaneous injection has great clinical value. Consistent with Simcere’s mission, we will make joint efforts to make better medicines available to patients sooner.”